BBNX — Beta Bionics, Inc. Common Stock

Beta Bionics, Inc. Common Stock (BBNX) is a medical devices company listed on NASDAQ. It is led by Sean T. Saint PE, based in 11 Hughes, Irvine, CA, United States, 92618, with about 420 employees. Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Latest reported BBNX revenue for 2025-09-30 was $27.3M. Net income was -$14.2M. Revenue was up 17.3% from 2025-06-30 to 2025-09-30. BBNX currently screens at market cap $640.8M.

Use this BBNX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BBNX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BBNX SEC filings page. Lician reads the product cache first so this HTML stays unique to Beta Bionics, Inc. Common Stock even when a live quote feed is slow.